Iveda Solutions SEC Filings

Iveda Solutions, Inc. (IVDA) filed a prospectus supplement registering up to 1,296,876 shares of common stock issuable upon exercise of outstanding Series A, Series B and placement agent warrants. Alongside this, the company reported Q3 2025 revenue of $1.65 million, down from $2.40 million a year earlier, but narrowed its net loss to $221,304 from $581,373 as gross margin improved. For the nine months ended September 30, 2025, revenue rose to $4.65 million from $4.28 million and the net loss improved to $1.58 million from $2.47 million, helped by lower operating expenses. Cash, restricted cash and equivalents totaled $3.33 million at period end, and Iveda subsequently raised $2.22 million of additional equity via its at-the-market program. Despite these improvements, management and the auditor concluded that recurring losses and negative operating cash flow raise substantial doubt about the company’s ability to continue as a going concern.

Iveda Solutions, Inc. (IVDA) filed a prospectus supplement that updates an existing resale registration covering warrants to purchase 411,185 shares of common stock and pre-funded warrants to purchase 273,685 shares of common stock, incorporating its latest Quarterly Report on Form 10-Q for the period ended September 30, 2025.

For the nine months ended September 30, 2025, Iveda generated total revenue of $4.65 million, up from $4.28 million a year earlier, with most sales coming from Taiwan government and commercial customers. The company reduced its net loss to $1.58 million from $2.47 million, and total stockholders’ equity increased to $3.77 million, helped by equity issuances including at-the-market sales. Cash, restricted cash and equivalents were $3.33 million at period end, and an additional $2.22 million was raised in October 2025.

Despite these improvements, management and the auditors state that recurring losses, negative operating cash flow and an accumulated deficit of $54.76 million raise substantial doubt about Iveda’s ability to continue as a going concern.

Iveda Solutions, Inc. is updating a prospectus covering warrants to purchase 235,625 shares of common stock at $34.00 per share, by incorporating its latest Form 10-Q. For the quarter ended September 30, 2025, revenue was $1.65 million, down from $2.40 million a year earlier, but the net loss narrowed to $0.22 million from $0.58 million as operating expenses fell. For the nine-month period, revenue rose to $4.65 million from $4.28 million and the net loss improved to $1.58 million from $2.47 million.

Cash, restricted cash and equivalents were $3.33 million, supported by equity raises including 1,599,383 shares sold through an at‑the‑market program for net proceeds of $2.71 million, plus an additional 1,373,809 shares in October 2025 for $2.22 million. Despite these financings and improved results, the company reports an accumulated deficit of $54.76 million and states that there is substantial doubt about its ability to continue as a going concern.

Iveda Solutions (IVDA) filed its Q3 2025 10‑Q, showing lower quarterly revenue but a smaller loss. Q3 revenue was $1,651,787 versus $2,398,162 a year ago, with gross profit of $517,277. Operating loss narrowed to $214,303 and net loss to $221,304 (from $581,373). For the nine months, revenue reached $4,654,270, up from $4,278,983, while net loss improved to $1,579,225.

Cash and cash equivalents were $3,298,474 at September 30, 2025, and stockholders’ equity was $3,768,242. Management disclosed substantial doubt about the company’s ability to continue as a going concern due to ongoing losses and negative operating cash flows. The company raised capital through an at‑the‑market program, selling 1,599,383 shares for net proceeds of $2,706,346 year‑to‑date and, subsequently in October, 1,373,809 shares for $2,224,048.

Customer concentration remains high: four customers accounted for 66% of revenue for the nine months, primarily in Taiwan. Common shares outstanding were 4,457,444 as of September 30, 2025, and 5,874,741 as of October 31, 2025.

Iveda Solutions (IVDA) director reports share disposition. A Form 4 shows a director disposed of 20,331 shares of common stock on 10/21/2025 at a price of $1.28 per share. Following the transaction, the reported beneficial ownership was 0 shares, held directly. The form was signed by Robert D. Gillen.

Iveda Solutions (IVDA) filed a resale registration for up to 1,296,876 shares of common stock. The shares are issuable upon exercise of Series A and Series B warrants at $3.44 per share (five-year and 18‑month terms, respectively) and placement agent warrants for 46,876 shares at $4.30 per share, all tied to the September 2024 offering. The company is not selling shares in this filing and will not receive proceeds from sales by the selling stockholders.

The company would receive cash only if holders exercise the warrants for cash, which would total approximately $4.4 million at full exercise. The common stock last closed at $1.28 on October 21, 2025. Shares outstanding were 5,879,741 as of the prospectus date. The Nasdaq Capital Market listing remains “IVDA.”

Iveda Solutions, Inc. discloses executive compensation, option awards and insider holdings in its definitive proxy. The filing shows David Ly as Chairman and CEO with total 2023 compensation of $225,827 (base $190,000), and other named executives with 2023 pay in the low six‑figures. The document lists multiple stock option grants to executives with specific grant dates, quantities and exercise prices — for example, 15,000 options to the CEO and 15,000 to the CFO on 12/7/2024 at an exercise price of $1.71. Reported beneficial ownership stakes for directors and named officers are small (generally under 1%), showing limited insider concentration. The filing primarily addresses governance and compensation rather than operational or earnings data.